# EarlySight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/earlysight

- Industry: Medical Devices & Equipment
- Headquarters: Geneva, Switzerland
- Website: www.earlysight.com
- Total disclosed funding: $6.4M
- Latest round: Seed (Sep 8, 2025)
- Investors on record: 6

## About

EarlySight SA specializes in advanced ophthalmic imaging technology, providing high-resolution retinal imaging to enhance early detection and monitoring of eye diseases.Founded in 2019, EarlySight SA is located in Geneva, Switzerland, and focuses on developing an innovative ophthalmic camera. In September 2025, EarlySight SA raised CHF 3.1 million in seed funding from returning investors Verve Ventures, Nina Capital, NovaCapital, and Cadfem Group. New investors Zurich Cantonal Bank and FONGIT also participated in the round. The founding team consists of Christophe Moser, Mathieu Kunzi, and Timothé Laforest, who serves as the CEO. EarlySight's core offering is its innovative ophthalmic camera, designed to provide high-resolution imaging of the retina at a cellular level. This advanced optical instrument utilizes disruptive infrared transscleral flood illumination combined with adaptive optics to deliver detailed images of retinal structures such as the retinal pigment epithelium (RPE), photoreceptors, and nerve fiber layers. The technology facilitates precise detection and monitoring of eye diseases, addressing significant unmet medical needs in the field of ophthalmology. By enabling healthcare professionals to observe individual cells impacted by diseases, EarlySight aims to enhance early diagnosis, track disease progression, and evaluate treatment effects. The company's products target eye care professionals and institutions, including hospitals and specialized clinics across multiple geographical markets, including Europe, North America, and Asia, catering to a global clientele concerned with retinal health.EarlySight generates revenue primarily through the sale of its flagship imaging device and associated software solutions to hospitals, clinics, and research institutions. The company engages in direct-to-consumer and B2B transactions, focusing on partnerships with eye care professionals. Its revenue structure includes one-time equipment sales along with ongoing service contracts for software updates and support. Additionally, as the AI software for analyzing images and detecting disease biomarkers is developed, it is anticipated to enhance the company’s revenue streams by offering subscription-based analytics services. The transaction model aims to create long-term relationships with healthcare providers, ensuring they have access to imaging technology and ongoing support as they monitor patients with retinal diseases. The company plans to utilize the September 2025 funding to accelerate growth, support the launch of Cellularis, enable commercial partnerships, and advance U.S. regulatory approval of the imaging device.

## Funding rounds

- Seed, Sep 8, 2025, $3.9M — Zurich Cantonal Bank, Verve Ventures, Nina Capital, FONGIT, NovaCapital, Cadfem Group
- Seed, May 26, 2021, $2.6M — Nina Capital, Verve Ventures

## Investors

- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed
- Zurich Cantonal Bank — Seed
- FONGIT (https://capitalatlas.ai/funds/fongit) — Seed
- NovaCapital (https://capitalatlas.ai/funds/novacapital) — Seed
- Cadfem Group — Seed